

SUBJECT INDEX

A

Aarskog syndrome, 622
 Acetosyringone (AS), 3-5
Achlya ambisexualis, HSP90 and, 638
 Acoustic neurofibromatosis, genetic markers and, 272-275
 Activation phenomenon, and gene dosage, 66-67
 Adenomatous polyposis, genetic markers and, 272-275
 Adrenal hypoplasia (AHC), and muscular dystrophy, 605-606
 African Green Monkey, SV40 and, 511
 African trypanosomes, *See* Trypanosomes
 AGFAP (Antigen Genotype Frequencies Among Patients), 40
Agrobacterium tumefaciens, 1-25
 actions of, 1-6
 asexual gene transfer in tomatoes, 294-296
 crown gall tumors and, 1-2
 definition of, 1
 F plasmid conjugation and, 16-19
 genetic components, 2-4
 natural plant engineering via Ti plasmid, 422-428
 vir control and, 3-6
 AHC (Adrenal hypoplasia), and muscular dystrophy, 605-606
 Aicardi syndrome, 622
 Alleles,
 of DHPR gene, 308
 gene dosage effects on hyperphenylalaninemia, 310
 of HLA genes, 35-37
 human imprinting mechanisms and, 139-140
 multisite haplotypes and, 262-263
 negative allelic complementation defined, 310
 of PAH gene, 306-307
 population genetics of variant alleles, 306-308, 313-314
 recombination and repeated genes, 149
 Alpha-amanitin, 112

Amino acids,
 DHPR gene and, 308
 PAH cDNA cloning, 305
 PAH gene and, 305-308
Anabena, 81
 Androgenones, development of in mammals, 130
 Aneuploidy, 52-70
 aneuploidy-induced lethality, 59-60
 dosage effects, molecular consequences of, 63-70
 gene dosage and, 54-56
 macromolecule assembly, 69
 pathogenesis of aneuploidy phenotypes, 60-62
 phenotypes in humans, 56-63
 regulatory system effects, 65-68
 Angiogenesis, in transgenic mice, 508
 Anhydrotic ectodermal dysplasia, 622
 Aniridia, 621-622
 Ankylosing spondylitis (AS), and HLA genes, 35-37
Anthoxanthum odoratum, 141
 Antigen gene, 107-121
 expression site in trypanosomes, 109-110
 molecular basis for timing of expression, 116-118
 p72 and HSP70 interactions with cellular tumor antigens, 650-651
 repertoire in trypanosomes 108-109
 single site expression site mechanisms, 112-114
 stage-dependent regulation of expression sites, 118-120
 telomeres available to, 109
 transcription unit and expression site, 110-112
 variation in blood, 114-116
 Antigen Genotype Frequencies Among Patients (AGFAP), 40
 Antigenic variation, *See* Antigen gene
 Antisense RNA, 568-594
 advantages of regulation by, 593-594
 artificial, 594
 ColEI plasmids and, 568-570, 574-577

control,
 bypass of by preventing read-through transcription, 584-585
 RNA-IN and RNA-OUT, 584
 and CRP/TIC, 574
 and *Escherichia coli*, 573-574
 FinP/IraI interactions, 570-571
 and GRP 78 protein in mammalian cell line, 651
 inhibition effects, 579-584
 inhibition of gene expression and, 582-584
 IS10, 589-591
 multicopy inhibition, 571
 synthesis and stability, 574-577
 loop mutations, 577-579
 single-base, 578
 and *micF* gene, 573-574
 mutations, 577-579
ompC, *ompF*, *OmpR* proteins and, 573-574
 P22 *sar* and, 574
 p22 *sar* pairing reactions, 591-592
 pairing effects, reaction types compared, 592-594
 pairing effects, 581-594
 mechanisms of, 585-594
 phylogenetic differences, 577-579
 plasmid antisense systems, 568-571
 RNA-OUT and, 574-577
ticRNA and, 574
sar, 571-573
 stem-loop structures, 574
 synthesis and stability, 574-577
 and temporal regulation of phage development, 571-573
tolC and, 573-574
 transcriptional effects and RNase III cleavage, 582
 Antithrombin III, deficiencies of, 64
 Alpha 1 -antitrypsin, 64
Arabidopsis species, morphogenesis, 356-357
Arabidopsis thaliana, DNA transfer and, 20

- Aromatic amino acids,
 hydroxylase reactions, 303-305
 and hyperphenylalaninemia, 303
- Artificial Antisense RNA, 594
- Artiodactyls,
 gene maps, 341-344
 See Mammals
- AS (acetylsyringone), 3-5
- AS (ankylosing spondylitis), and HLA genes, 35-37
- Ashkenazi Jews, population genetics of variant alleles, 313-314
- ATP, p72 and HSP70 binding, 650
- ATPase activity, and heat-shock proteins, 644-654
- attB*, mechanisms of genetic recombination and, 83-91, 96
- attL*, mechanisms of genetic recombination and, 87-91, 96
- attP*, mechanisms of genetic recombination and, 87-91, 96
- attR*, mechanisms of genetic recombination and, 87-91, 96
- Autosomal damage,
 in *Drosophila*, 54-55
 in *Xenopus*, 55
 See also Aneuploidy;
 Oncogenes; Mutations;
 Phenotypes; Tumorigenesis
- Aviemore model, 171-173
- Axolotl, 140-141
- SazaCR, X-chromosomes and, 213-214
- B**
- B-cell lymphoma, 493
 and secondary events as progression to neoplasia, 505
- B-cell tumors, 501
- B-VATs, antigen expression and, 119-120
- Bacillus subtilis*, and recombination, 175
- Bacillus thuringiensis*, tomato plant genetics, 295
- Bacteria,
 bacterial conjugation versus T-DNA transfer, 16-19
 See also *Agrobacterium tumefaciens*
- Bacteriophages,
 CSSR and, 80
 and *groE* genes of *E. coli*, 652-653
 T4 recombination, 170
 temporal regulation of phage development, 571-573
 See also Phage lambda;
 specific phages by name
- Bam*HI-cleaved plasmid, pERT reassociation and, 607-609
- Becker muscular dystrophy,
 carrier identification, 614-616
 classical genetics of, 602-603
 creatine kinase (CK) and, 602-603
 Haldane rule calculations, 603
 Mbol and, 606-612
 molecular genetics of, 603-612
 mutations and, 612-616
 pathogenesis of, 619-621
 pERT reassociation and, 607-609
 prenatal diagnosis, 614-616
 X/autosome translocations, 622
- Beckwith-Wiedemann syndrome, 621-622
- BH 2, 302-303
 and hydroxylation reaction, 303
- BH 4, 303-314
 cofactor and hydroxylation reaction, 303
 diagnosis of deficiencies, 312
 and enzyme phenotypes, 309
 and hydroxylation reaction, 304
 treatment approaches for deficiencies, 311-312
- Bip-immunoglobulin complexes, in mammalian cells, 651
- BK virus, pathological consequences, 491-492
- Blacks, population genetics of variant alleles, 306
- Blood, antigenic variation in, 114-116
- Bloodstream VATs (B-VATs), 119-120
- BMD, *See* Becker muscular dystrophy
- Bootstrap method, in studying phylogenies, 548, 550-552
- Border nicking, of DNA molecules, 9-14
- Bovine papillomavirus type 1 BPV-1, *See* BPV-1
- BPV-1, 235-254, 510
 biology of, 236-237
 cellular transformation, 244-245
 coordinate regulation, 251-253
 E2 factors in viral transcription, 240-244
 late gene expression, 250-251
 mutations, 247-249
 physical map, 237
 plasmid replication, 245-249
 replication mechanisms, 245-251
 two-stage model of, 245-251
 trans-acting factors and plasmid replication, 246-249
 and tumorigenesis in transgenic mice, 492
 viral DNA replication, 245-251
 viral transcription, 237-244
 See also Viral transcription, of BPV-1
- Brachydanio rerio*, cloning of, 140-141
- Branch length variance, as statistical tests of phylogenies, 542
- Brugia malayii*, heat-shock proteins and, 633
- C**
- C. elegans*, small HSPs and, 653-658
- C. elegans* (*Caenorhabditis elegans*), gene dosage effects, 58-59
- c-fos*,
 and hyperplasias without frequent progression to tumors, 503-505
 protein coding, 497-498
- c-Ha-ras* oncogene, dosage effects, 66
- c-myc* genes, 493-494
 and imprinting of genome, 136
 and induction of preneoplastic states, 501
 and oncoprotein action, 499-501
- Caenorhabditis elegans*, gene dosage effects, 58-59
- Calmodulin, HSP90 and, 638
- CAM (Cell adhesion molecule), 68-69
- Canadian populations, population genetics of variant alleles, 306
- Canalization, definition of, 360-361

- Cancer,
associated with deletion of
human chromosome re-
gion 13q14, 67
chromosome characterization,
276-277
embryonal carcinoma cell ex-
pression of X-
chromosome, 203-205
epidemiology of, 479
genetics of, 479-514
hyperplasias without frequent
progression to tumors,
503-505
induction of preneoplastic
states, 500-505
oncogenes and natural regula-
tory elements, 484-492
oncogenes in transgenic mice,
482-491
and oncoprotein action, 499-
501
pancreatic oncogenesis in
transgenic mice, 495-
496
targeted expression of hybrid
oncogenes, 493-497
transformation of lymphoid
cells, 493
transformation of mammary
glands, 493-494
See also Oncogenes; Onco-
proteins; Tumorigenesis;
Tumors
Canidae, chromosome shuffles
in, 340-341
CAP protein, and transcription
of bacterial genes, 574
Carnivores, genome organization
compared with humans,
336-341
Carrier identification, of muscu-
lar dystrophy, 614-616
Cavender's confidence interval,
537-539
CD (celiac disease), and HLA
genes, 35-37
Celiac disease (CD), and HLA
genes, 35-37
Cell adhesion molecule (CAM),
68-69
Cell-type specific tumors, and
hybrid oncogenes, 496
Cellular interactions, types of,
68-69
Cellular localization, of heat-
shock proteins, 641-642
Cellular transformation, by
BPV-1, 244-245
Celtic populations, population
genetics of variant alleles,
313-314
*Centre d'Etude du Polymor-
phisme Humain* (CEPH),
265-267
CEPH (*Centre d'Etude du Poly-
morphisme Humain*), 265-
267
CGD (chronic granulomatous
disease), 622
CGD (Chronic granulomatous
disease), and muscular
dystrophy, 605-606
Chagas disease, 633
CHEF/18 (Chinese hamster cell
line), tumorigenicity of, 66
Chi, 177-192
properties of, 176-177
Smith's nick-at-Chi model,
178-179, 187-191
Chimeras, development of, 131-
132
Chimeric genes, plant gene vec-
tors derived from the Ti
plasmid
and, 424-427
Chinese, population genetics of
variant alleles, 313-314
Chinese hamster cell line
(CHEF/18), tumorigenicity
of, 66
Choroid plexus tumors, 491,
493, 500, 511
Choroideremia, genetic markers,
272-275
Chromatids, recombination and
repeated genes, 148-149
Chromatin, structure of and
DNA methylation, 213-218
Chromosomes,
abnormalities in humans, 56-
63
aneuploidy, 52-70
antigen gene expression and
control, 107-121
antisense control and, 573-
574
complete coverage of, 267-
269
DHPR gene and, 308
DNA methylation and X-
chromosome expression,
200-202, 210-224
eukaryotic and recombination
and repeated genes, 148-
149
gene dosage effects on hyper-
phenylalaninemia, 310
genetic markers for human
chromosomes, 259-277
genetic markers of human dis-
eases and, 272-275
human genetic map, 261-262
human region 13q14, 67
mapping of DNA markers,
265-266
marker map characteristics,
271-272
and molecular genetics of
muscular dystrophy, 603-
612
multisite haplotypes and, 262-
263
and muscular dystrophy, *See*
Becker muscular dys-
trophy; Duchenne muscu-
lar dystrophy; muscular
dystrophy
oogenetic expression and X-
chromosome, 201-202
PAH gene and, 305-308
population genetics of variant
alleles, 306-308, 313-314
Robertsonian translocations
during gametogenesis in
mice, 132-134
tumor chromosome
characterization, 276-277
x reactivation mechanisms,
221-224
X-chromosome expression,
199-224
See also X-chromosome
X-chromosome regulation,
216-224
See also Genetics; Pheno-
types; X-chromosome
Chronic granulomatous disease
(CGD), 622
and muscular dystrophy, 605-
606
cII gene, 572-573
Cin system, and genetic
recombination, 81-82
CK activity, carrier identifica-
tion of muscular dystrophy
and, 614-616
CK (creatine kinase), and
muscular dystrophy, 602-
603
Clathrin uncoating ATPase, 649-
650
CloDF13 plasmids, 568-571
Cloning,
of *Brachydanio rerio*, 140-
141
DHPR gene, 308
of DNA segments from DMD
gene, 606-612
of HRPT genes, 214
of maize, 362-363
of PAH gene, 305
of PGK genes, 215
phenol enhanced reassociation
technique (pERT), 606-
612

- CNS, neuronal differentiation in, 500
- Cohesive end site, *See Cos*
- ColEI plasmids, antisense inhibition effects, 579-584
and antisense RNA, 568-570
loop mutations, 577-578
pairing effects and antisense, 581-582
phylogenetic differences, 577-579
Rom/Rop protein and, 589
stability of, 574-577
and stem-loop structures of antisense RNA, 574
synthesis of, 574-577
transcriptional effects and RNase III cleavage, 582
- ColEI plasmids, pairing reaction mechanisms, 585-587, 592-594
- Computer software, GMS (Gene mapping system) program, 268
LINKAGE program, 264-265, 274
- Conjugation, 16-19
- Connective tissue disorders, 62
- Conservative site-specific recombination, definition of, 78
See also CSSR; Genetic recombination; Site-specific recombination
- Contiguous gene syndromes, 621-623
- Corn, *See* Maize
- cos*, definition of, 173
and recombination, 173-177
- Cos*, standard operations, 176-177
- Coxiella burnetii*, 633
- Cre recombination, 83-86, 94
- Creatine kinase (CK), and muscular dystrophy, 602-603
- Crepis capillaris*, DNA transfer and, 20
- Crick strands, 95
- CRM, gene dosage effects on hyperphenylalaninemia, 310
positive and negative phenotypes, 309
- Crop improvement, engineering applications in plant genetics, 457-460
- Cross-reacting material (antigen), *See* CRM
- Crown gall tumors, 1-2
control of tumor forming activity, 7-8
- CRP protein, and transcription of bacterial genes, 574
- CSSR, assessment of, 97
definition of, 78
DNA alterations, 78-80
higher-order nucleoprotein complexes and, 90-91
mechanisms of genetic recombination and, 82-95
plasmid segregation, 81
transposon cointegrate resolution, 80-81
- CSSR (conservative site-specific recombination), *See* Genetic recombination; Site-specific recombination
- CYC1 gene, and intrachromosomal mitotic recombination, 155
- CYC7 gene, and heterochromosomal mitotic recombination, 156
- cycl-11* mutation, 156
- Cystic fibrosis, 313
genetic markers and, 272-275
- Cytogenetics, and recessive changes, 509-510
- Cytosolic protein, 634-639
- D
- D. melanogaster*, *See* *Drosophila*
- Danish populations, population genetics of variant alleles, 306
- DDK mice, and non-DDK incompatibility, 134-135
- Delete-half method, in studying phylogenies, 552
- Dermal fibromatoses, 509-510
- Determination, definition of, 359
of meristems, 359-362
- DHPR, 302-313
diagnosis of deficiencies, 312
and enzyme phenotypes, 309
gene dosage effects on hyperphenylalaninemia, 310
and hydroxylation reaction, 303-305
and neurotransmitter depletion, 311
population genetics of variant alleles, 313-314
purification of, 305
- DHPR gene, 308
alleles of, 308
chromosomal placement, 308
- Diabetes, 31
IDDM, 31, 35-37, 43-46
NIDDM distinguished from IDDM, 43
- Dicystostelium*, heat-shock proteins and, 656
- Didelphis virginiana*, X-chromosome expression, 209
- DiGeorge syndrome, 621-622
- Dihydrobiopterin synthase, 304-305
- Dihydrofolate reductase locus, and resistance to methotrexate, 53
- Dihydropteridine reductase, *See* DHPR
- Dihydroxyphenylalanine (DOPA), 303-306
- Dimorphic pathogens, heat-shock proteins of, 632-633
- Disease, Aarskog syndrome, 622
acoustic neurofibromatosis, 272
adenomatous polyposis, 272
Aicardi syndrome, 622
ankylosing spondylitis, 35-37
Beckwith-Wiedemann syndrome, 621-622
cancer, 67, 203-205, 276-277, 479-514
choroideremia, 272
chronic granulomatous disease, 605-606, 622
cystic fibrosis, 272, 313
diabetes, 31, 35-37, 40-47, 495, 505-508
Duchenne muscular dystrophy, 52, 272, 602-623
genetic mapping and, 272-277
high-density mapping techniques, 275-277
HLA disease, 37-43
Hunter syndrome, 622
Huntington's disease, 272, 308
influenza, 651
Langer-Giedon syndrome, 621-622
malaria, 633
multiple endocrine neoplasia, 272, 277
multiple sclerosis, 35-37
muscular dystrophy, 52, 272, 602-623
peripheral neurofibromatosis, 272, 308
Q fever, 633
retinitis pigmentosa, 272

- rheumatoid arthritis, 31, 35-37
- sickle cell anemia, 313
- spastic paraplegia, 272
- tuberculosis, 633
- See also Bacteriophages;
- specific diseases by name
- Distance matrix methods, 526-528, 530-532
- Distance methods, in studying phylogenies, 541-543
- DMD, See Duchenne muscular dystrophy
- DMD gene,
- cartography of, 612
- cloning of DNA segments and, 606-612
- and contiguous gene syndromes, 622
- dystrophin and, 616-619
- isolation of expressed sequences from 609-612
- mutations, 612-616
- See also Duchenne muscular dystrophy
- mDMD gene, animal studies, 620-621
- DNA, 113, 114, 510
- accessory proteins in genetic recombination, 88-91
- Agrobacterium tumefaciens* and, 1-25
- chromosomes, 294-296
- antigen gene expression site and, 110
- antisense RNA inhibition, 579-584
- asexual gene transfer in tomatoes and, 294-296
- axolotl development, 140-141
- binding sites and mechanisms of genetic recombination and, 82-90
- border nicking, 9-14
- bovine papillomavirus type 1 (BPV-1), 235-254
- carrier identification of muscular dystrophy and, 614-616
- Chi-containing, 177-178
- cloning,
- of bacteria, 14-141
- and Duchenne muscular dystrophy, 606-612
- of HRPT genes, 214
- of maize, 362-363
- Mbol* and, 606-612
- of PAH gene, 305
- pERT technique, 606-612
- of PGK gene, 215
- CSSR alterations, 78-80
- developmental excision, 81
- direct gene transfer techniques, 431-434
- directional transfer of donor DNA, 16
- double chain breaks, recBCD and, 170-187
- double-chain breaks, 169-192, 170-187
- phage lambda repair, 178-182
- yeast repair, 182-187
- dystrophin and, 617-618
- F plasmid conjugation, 16-19
- gene mapping methodology, 326-328
- genes under *vir* control, 3-6
- genetic markers for human chromosomes, 259-277
- genetic map, 261-262
- multisite haplotypes, 262-263
- VNTR systems, 263-264
- genetic recombination, higher-order nucleoproteins, 90-91
- hDNA and double-chain breaks, 170-175
- heat-shock proteins and, 632-667
- heterochromosomal recombination, 152-153
- mitotic, 156-157
- HSP70 and, 641-652
- HSP90 and, 636-639
- integrase family, 87-88
- intrachromosomal gene conversion, 150-151
- intrachromosomal reciprocal exchange, 151-152
- liposome-encapsulation of, 434-435
- in mammalian cells, 648-653
- mammalian imprinting mechanisms and, 136-142
- markers and disease, 275-277
- mechanisms of genetic recombination and, 82-95
- substrate DNAs and recombination proteins, 83-91
- and meiotic ectopic recombination, 149-153
- mitotic ectopic recombination, 153-157
- muscular dystrophy and molecular genetics of DNA, 605-606
- phage lambda, 177-192
- replication, 645-648
- and plant genetics, 422-460
- recombinases, 86-87
- recombination,
- Aviemoire (Meselson-Radding model), 171-173
- cos*, 173-177
- and lambda red system, 175-177
- prokaryotes and, 157-161
- Resnick's model, 170-173
- replication mechanisms, plasmid replication, 245-249
- trans*-acting factors and plasmid replication, 246-249
- viral 245-251
- resolvases, 91-94
- strand exchange, 91-97
- Crick strands, 95
- Holliday structures, 94-96
- mechanisms of, 94-97
- synapsis and, 91-94
- Watson strands, 95
- substrate requirements, 83-84
- synapsis recombination, 91-94
- synthesis of, antisense inhibition effects, 579-584
- T4, 170
- T-strand as transfer intermediate, 10-17
- transfer process, 1-25
- bacterial conjugation versus T-DNA transfer, 16-19
- E2 factors in viral transcription, 240-244
- F plasmid, 18
- integration of T-DNA into plant genome, 19-22
- intermediates, 9-15
- mating pair stabilization, 19
- overdrive sequence, 8-9
- structural requirements, 6-9
- T-DNA borders, 7-11
- T-strand as transfer intermediate, 10-17
- and transgenic mice, 481-482
- transposon cointegrate resolution, 80-81
- and tumorigenesis, 491-512
- unequal recombination between homologous chromosomes, 153
- viral replication, 245-251
- X-chromosome expression, 200-202
- See also X-chromosome
- X-chromosome expression, in extraembryonic lineages, 206-208
- See also T-DNA

- cDNA,
 carrier identification of
 muscular dystrophy and,
 614-616
 cloning and DMD genes,
 618-619
 DMD gene and, 609-616
 dystrophin structure deduced
 from, 617-618
 library and DHPR clones, 308
 mouse NIH 3T3 and, 312
 PAH cloning, 305
 and PAH gene, 308
 and PAH monomer, 303
 and transgenic mice, 482
- hDNA,
 Aviemore (Meselson-Radding
 model), 171-173
 and double-chain breaks, 170-
 175
- rDNA, chromosomal organiza-
 tion, 111
- DNA binding, 12-18
 E2 factors in viral transcrip-
 tion, 240-244
- DNA markers,
 CEPH collaboration, 265-267
 mapping of, 265-266, 272-
 277
See also Genetic markers
- DNA methylation,
 onset of, 218
 and X-chromosome expres-
 sion, 200-202, 210-224
See also DNA
- DNA recombination, 77-97
See also Genetic recombina-
 tion
- DNAase, and transgenic mice,
 481-482
- DNAase I, 113
 antigen gene expression site
 and, 110
- DnaK, HSP70 and, 645-648
- DOPA, 303-306
- Double-chain breaks, 170-192
 and DNA repair, 169-192
 phage lambda repair, 178-182
 and recBCD, 170-187
 yeast repair, 182-187
- Down syndrome, 61
 and cell adhesiveness, 68
- Drosophila*, 54-55, 63, 362
 aneuploidy-induced lethality,
 59-60
 embryos and heat-shock pro-
 teins, 662
 gene dosage effects, 58-59,
 65-66
 heat-shock proteins and, 632-
 633
 HSP70 and, 641-642
- p72 and HSP70 binding, 650
 small HSPs and, 653-658
 wing development abnormali-
 ties, 68
- Duchenne muscular dystrophy,
 52, 602-623
 AHC (Adrenal hypoplasia)
 and, 605-606
 carrier identification, 614-616
 CGD (Chronic granulomatous
 disease) and, 605-606
 classical genetics of, 602-603
 creatine kinase (CK) and,
 602-603
 description of, 602
 DMD gene mutations, 612-
 616
 DNA cloning and, 606-612
 dystrophin and DMD gene,
 616-619
 dystrophin localization in
 muscle cells, 618-619
 Emery-Dreifuss muscular
 dystrophy and, 620-621
 glycerol kinase (GK) de-
 ficiency and, 605-606
 Haldane rule calculations, 603
 incidence of, 603
 McLeod phenotype (XK) and,
 605-606
Mbol and, 606-612
mdx gene (mouse) and, 620-
 621
 mental retardation and, 605-
 606
 molecular genetics of, 603-
 612
 pathogenesis of, 619-621
 phenol enhanced reassociation
 technique (pERT), 606-
 612
 prenatal diagnosis, 614-616
 retinitis pigmentosa (RP) and,
 605-606
 RFLP markers, 604-605
 X-autosome translocations,
 622
- Dystrophin, 616-619
 cDNA sequence and, 617-618
 expression of DMD gene, 617
 muscle cell localization, 618-
 619
- E
- E2 factors, in viral transcription
 of BPV-1, 240-244
- EC (embryonal carcinoma) cells,
 cytodifferentiation, 205-206
 X-chromosome expression
 and, 203-205
- Ectopic recombination,
 biological significance be-
 tween repeated genes,
 162
 heterochromosomal
 recombination, 152-153
 intrachromosomal gene con-
 version, 150-151
 intrachromosomal reciprocal
 exchange, 151-152
 meiotic, 149-153
 mitotic heterochromosomal
 recombination, 156-157
 mitotic intrachromosomal
 recombination, 154-156
 prokaryotes, 157-161
 unequal recombination be-
 tween homologous
 chromosomes, 153
 in yeast, 153-157
- EDMD (Emery-Dreifuss muscu-
 lar dystrophy), 620-621
- EDR1 gene, 155
- EDR1 system, and ectopic
 recombination, 163
- Elastase promoters, 495-496
- Elastase-T antigen transgene,
 501
- Embryonal carcinoma (EC)
 cells, *See* EC cells
- Embryonic cancer cells (EC),
 cytodifferentiation, 205-206
- Embryonic lineages, X-
 chromosome inactivation
 in, 209-213
- Emery-Dreifuss muscular dystro-
 phy (EDMD), 620-621
- Endoplasmic reticulum, and
 HSP70 function, 646-648
- envZ*, 573-574
- Enzymes,
 gene dosage effects, 64-66
 on hyperphenylalaninemia,
 309-310
 PAH regulation and, 304
 phenotypes, 308-310
- EPSP synthase, and tomato
 plant genetics, 296
- D-erythro-7,8-dihydroneopterin
 triphosphate, 304-305
- ESAG (Expression Site Associ-
 ated Genes), 109-112
 "companion sequence", 116
- Escherichia coli*, 4-6, 15, 16
- Agrobacterium* and natural
 plant engineering, 423-
 428
 antisense control and, 573-
 574
 antisense RNA and, 568
 CAP protein and, 574
 cDNA cloning and, 618-619

- CRP protein and, 574
 FIS and genetic recombination, 89
 gene mapping methodology, 326-328
 genetic analysis of HSP90, 639-640
groE genes and, 652-653
 and heat-shock proteins, 634-636, 661, 665-666
 homologous recombination, 173-174
 HSP70 and, 645-648
 HSP90 biochemistry and, 638
 Integration Host Factor (IHF) and, 80
 mutations and Hsp synthesis, 663-664
 p53 synthesis and DnaK, 650
 PAH cDNA and, 305
 recBCD, 175-176
 recombination and prokaryotes, 157-161
 small HSPs and, 653-658
 and temporal regulation of phage development, 571-573
tic RNA and, 574
 Estrogen, 637
 Eukaryotes,
 heat shocks and, 634-636
 heat-shock proteins, 659-661
 Eukaryotic chromosomes,
 recombination and repeated genes, 148-149
 Eukaryotic polymerases I and II, 111-112
 European populations, population genetics of variant alleles, 307, 313-314
 Evolution,
 mammalian genome organization and, 323-347
 phylogenies and, *See* Phylogenies
 Expression Site Associated Genes (ESAG), 109-112
 Extraembryonic lineages, X-chromosome expression in, 206-208
 F
 F plasmid,
 conjugation, 16-19
 mating signal in DNA transfer, 18
 SSB protein encoding, 18
 F tests, in studying phylogenies, 541
 Familial adenomatous polyposis, 272
 FBJ osteosarcoma virus LTR, 497
 Felidae, chromosome shuffles in, 338-341
 Fetus,
 and maternal hyperphenylalaninemia, 313
 See also Hyperphenylalaninemia
 Fibromatoses, 510-512
 dermal, 509-510
 Fibronectin synthesis, *c-Ha-ras* oncogene effects, 66
 Fibrosarcomas, and tumorigenesis in transgenic mice, 509-512
 Filariasis, 633
 Fim system, and genetic recombination, 82, 84-86
FinP, 570-571
FinP/traJ interactions, 570-571
 FIS,
 binding sites and mechanisms of genetic recombination and, 83-86
 and genetic recombination, 89
 FLP system, and genetic recombination, 82-86
 Focal islets, focal clusters and, 505-508
 Forensic, genetic markers used in, 277
 French populations, population genetics of variant alleles, 306
 FRT system, and genetic recombination, 85
 G
 G6PD gene, 215-216, 224
 X-chromosome expression in oogenesis and, 201-202
 Gametes,
 in mammalian development, 127-128
 See also Genes; Genetics
 GC to CG transversions, 590
 Gene dosage effects, 63-70, 309-310
 Gene mapping, 274-277, 324-345
 of artiodactyls, 341-344
 GMS system, 268
 of marsupials, 344-345
 methodology of, 326-328
 of primates, 328-331
 of tomato, 284-290
 See also Chromosomes; Genetic markers; Genes; Genetics
 Genes,
 aneuploidy and, 52-70
 antigen gene, 107-121
 B-VATs, 119-120
 cII gene, 572-573
 CYC1 gene and intrachromosomal mitotic recombination, 155
 CYC7 gene and heterochromosomal mitotic recombination, 156
 development of chimeras, 131-132
 DHPR gene, 308
 DMD gene, 606-612
 cartography of, 612
 dystrophin and, 616-619
 isolation of expressed sequences from, 609-612
 mutations, 612-616
 See also Duchenne muscular dystrophy; muscular dystrophy
 mDMD gene animal studies, 620-621
 DNA methylation and X-chromosome expression, 200-202, 210-224
 dosage effects, 54-56
 on hyperphenylalaninemia, 309-310
 molecular consequences of, 63-70
 EDR1 gene, 155
 ESAG genes, 109-112
 FinP/traJ interactions, 570-571
 G6pd gene, 215-216
 glyceraldehyde-3-phosphate dehydrogenase gene, 606
 GlyS gene, 158
 GlyT gene, 158-160
 Gpd gene and X-chromosome expression, 209
 groE genes of *E. coli*, 652-653
 His4 gene and intrachromosomal gene conversion, 151-152
 HPRT genes and X-chromosome expression, 209
 htpG gene, 640
 human genetic map, 261-262
 inhibition of gene expression, 582-584
 KAR2 gene, 642, 645
 Lac-I gene, 159
 LEU2 gene and intrachromosomal gene conversion, 151
 M-VATs, 119-120

- marker map characteristics, 271-272
mdx gene (mouse), 620-621
micF gene, 573-574
 "mini-exon", 111-112
 muscular dystrophy and, *See* Becker muscular dystrophy; Duchenne muscular dystrophy; muscular dystrophy
 oncogenes, 480-514
 PAH gene, 305-308
 PGK-1 genes and X-chromosome expression, 209
 RAD52 gene products, 155
 recombination of repeated genes, 148-163
 repeated, mitotic ectopic recombination, 153-157
*sar*RNA and, 571-573
 SSA/SSB/SSC genes and, 642-645
Sup genes and heterochromosomal recombination, 152-153
tail and tumorigenesis in transgenic mice, 492
 and temporal regulation of phage development, 572-573
 of tomato, 281-297
See also Tomato
traP genes, 570-571
 transgenes, 135-136
 X-chromosome expression and, 199-224
See also X-chromosome
 x-linked housekeeping genes, 214-216
 x-linked nonhousekeeping genes, 216-218
See also Genetics; Oncogenes; Tumorigenesis
 Genetic disorders, contiguous gene syndromes, 621-622
 muscular dystrophy, 602-623
See also Disease; Duchenne muscular dystrophy; Muscular dystrophy; specific disorders by name
 X/autosome translocations, 622
 Genetic markers, 259-277
 CEPH collaboration, 265-267
 chromosome coverage, 267-268
 forensic applications, 277
 of human diseases, 272-275
 human genetic map, 261-262
 LINKAGE program, 264-265, 274
 mapping of DNA markers, 265-266
 marker map characteristics, 271-272
 multisite haplotypes, 262-263
 recombination frequency estimates, 269-270
 tumor chromosome characterization, 276-277
 VNTR systems, 263-264
See also Chromosomes; Genetics
 Genetic recombination, 77-97
 accessory proteins in, 88-91
 Avimore model, 171-173
 biological significance between repeated genes, 161-162
 cin system, 81-82
 CSSR alterations of DNA, 78-80
 developmental excision, 81
 DNA and double-chain breaks, 169-192
 DNA strand exchange and, 91-97
 DNA substrate requirements, 83-84
 fim system, 82
 and FIS, 89-90
 FLP system, 82
 gin system, 81-82
 hDNA and double-chain breaks, 170-175
 heterochromosomal mitotic recombination, 156-157
 heterochromosomal recombination, 152-153
 higher-order nucleoprotein complexes and, 90-91
 hin system, 81-82
 homologous and repeated genes, 148-149
 homologous versus site-specific, 77-78
 and HU, 89-90
 integration and excision systems, 80
 intrachromosomal gene conversion, 150-151
 intrachromosomal mitotic recombination, 154-156
 intrachromosomal reciprocal exchange, 151-152
 inversion systems, 81-82
 lambda red system, 175-177
 and lambda red system, 175-177
 mechanisms of, 82-95
 meiotic ectopic recombination, 149-153
 Meselson-Radding model, 171-173
 mitotic ectopic recombination, 153-157
 overlap homology, 83-84
 phage lambda and, 177-192
 pin system, 81-82
 plasmid segregation, 81
 and prokaryotes, 157-161
 of repeated genes, 148-163
 Resnick's model, 170-173
Saccharomyces cerevisiae, 82
Salmonella typhimurium, 81-82
 synapsis, 91-94
 and T4, 170
 transposon cointegrate resolution, 80-81
 unequal recombination between homologous chromosomes, 153
 Genetics,
Agrobacterium tumefaciens and natural plant engineering, 422-428
 aneuploidy, principles derived from human clinical material, 56-63
 aneuploidy and, 52-55
 antigen gene expression and control, 107-121
 of artiodactyls, 341-344
 asexual gene transfer of tomatoes, 294-296
 of BPV-1, 237-251
c-myc gene, 493-494, 499-501
 of *Caenorhabditis elegans*, 58-59
 of cancer, 479-514
 carnivore genome organization compared with humans, 336-341
 CEPH collaboration, 265-267
 contiguous gene syndromes, 621-622
 creatine kinase (CK) and, 602-603
 direct gene transfer, 431-434
 of disease, *See* Disease; specific diseases by name
 distance matrix methods, 526-528
 DNA methylation and X-chromosome expression, 200-202, 210-224
 dominant transforming genes, 480
 Down syndrome, 61

- of *Drosophila*, 54-59, 65-66, 632-658
 dystrophin and DMD gene, 616-619
 embryonal carcinoma cell expression of X-chromosome, 203-205
 forensic, 277
 genetic markers for human chromosomes, 259-277
 germline-specific imprinting of mammalian genomes, 132-135
 GMS program studies, 268
 Heilig walk, 610-612
 and HLA disease associations, 31-47
 of HSP90, 639-640
 human genetic map, 261-262
 human imprinting mechanisms, 139-140
 hybridization between
 Lycopersicon species and *Juglandifolia*, 293-294
 inferential methods, 524-529
 kissing reaction, 585-589
 LINKAGE program studies, 264-265, 274
 of maize, 356-379
 mammalian,
 development, 127-142
 genome organization, 323-347
 imprinting mechanisms, 136-142
 mapping of DNA markers, 265-266
 marker map characteristics, 271-272
 of marsupials, 344-345
 maternal and paternal genomes of mammals, 130-142
 metallothionein genes, 497
 MHC gene, 497
 mice genome organization compared with humans, 331-335
 MMTV and 493-494, 503-508
 MMTV-*c-myc* genes, 507-508
 monogenic versus aneuploidy disorders, 52-54
 morphogenesis and, 353-379
 multisite haplotypes, 262-263
 of muscular dystrophy, 602-623
 See also Becker muscular dystrophy; Duchenne muscular dystrophy; Muscular dystrophy mutations, 19, 313-314, 355-356, 363-373
- antisense RNA and, 577-579
 in DMD gene, 612-616
 and Hsp synthesis, 663-664
 and morphogenesis, 355-356
N-myc genes, 493
 and oncoprotein action, 499-501
 oogenetic expression and X-chromosome, 201-202
 parthenogenetic activation in mammals, 128-129
 pathogenesis of aneuploidy phenotypes, 60-62
 phenotypic maps, 58
 phylogenies, 521-560
 See also Phylogenies of PKU, 302-314
 plant gene vectors derived from the Ti plasmid, 423-428
 of plants, *See* Plant genetics of primates, 328-331
 recessive cytogenic changes, 509-510
 recombination frequency estimates, 269-270
 regulatory system effects and gene dosage, 66-68
 reverse genetics applications, 621-623
 of small HSPs, 653-658
 Smith's nick-at-Chi model, 178-179, 187-191
 statistical methods in studying phylogenies, 529-560
 See also Phylogenies; Statistics
 targeted expression of hybrid oncogenes, 493-497
 of tomato, 281-297
 See also Tomato tumor chromosome characterization, 276-277
v-abl gene, 493
vir gene expression, 3-6
 viral vectors and plant transformation techniques, 430-431
 WAP gene, 494
 X-chromosome expression, 199-224
 in preimplantation embryos, 202-203
 See also X-chromosome X-linked disorders, 52-53
 See also DMD gene
 See also Morphogenesis
 See also Plant genetics
- Genomes,
 development of parthenogenones in mammals, 129-132
 differential expressions, 128
 DNA methylation and X-chromosome expression, 212
 germline-specific imprinting, 132-135
 in mammalian development, 127-128
 mammalian organization, 323-347
 maternal mammalian, 130-142
 paternal mammalian, 130-142
 Germline-specific imprinting, of mammalian genomes, 132-135
 Gin system, and genetic recombination, 81-82
 GK deficiency, and muscular dystrophy, 605-606
 Beta-Globin, and transgenic mice, 481-482
 Glucagon promoters, 495-496
 Glucagonomas, 495
 Glucocorticoid receptors, 54, 637
 Glucose-regulated protein, 636
 Glyceraldehyde-3-phosphate dehydrogenase gene, 606
 Glycerol kinase (GK) deficiency, and muscular dystrophy, 605-606
GlyS gene, 158
GlyT gene, 158-160
 GM-CSF (colony stimulating factor), 503
 GMS (Gene mapping system) program, 268
Gpd gene, X-chromosome expression, 209
 GRP94 protein, 636
 GRP 78 protein, in mammalian cell line, 651
grpE encoding, 660
 GTP-CH, 302-314
 and enzyme phenotypes, 309
 and hydroxylation reaction, 303-305
 and neurotransmitter depletion, 311
 population genetics of variant alleles, 313-314
 purification of, 305
 Guanosine triphosphate, 302-314
 Guanosine triphosphate cyclohydrolase, *See* GTP-CH
 Gynogenetic inner cell mass (ICM), 131-132

- Gynogenones,
development of in mammals,
130
XO versus XY, 142
- H**
- H-2 promoters, 497-498
H-ras gene, 494
and hyperplasias without frequent progression to tumors, 503-505
Haldane rule, and muscular dystrophy, 603
Haplotypes, PKU alleles, 306-307
HBV genes, and regenerative induced by cell injury, 504
Heat, *See* Heat-shock proteins; Thermotolerance
Heat-shock proteins, 632-667
of dimorphic pathogens, 632-633
function of HSP70, 652
and HSP110, 634
and HSP90 family, 634-636
in mammalian cells, 648-652
as "Molecular chaperone", 640
mutations and Hsp synthesis, 663-664
p72 and HSP70 binding, 650
protective functions of, 633
response regulation, 665-666, 666-668
small HSPs, 653-658
SSA/SSB/SSC genes and, 642-645
thermotolerance, 639-640, 661-667, 661-663
ubiquitin and, 658-659
See also HSP70
Heilig walk, cloning and, 610-612
Heliothis zea, tomato plant genetics, 296
Hemachromatosis, 313
Hemangiomas, and oncoprotein specificity, 499
Heterochromosomal mitotic recombination, 156-157
Heterochromosomal recombination, 152-153
High-density mapping, 275-277
See also Genetic markers; G
Heliothis virescens, and tomato plant genetics, 296
Hin system, and genetic recombination, 81-82
Hip/him gene, and genetic recombination, 88
His 4 gene, and intrachromosomal gene conversion, 151-152
His 4 region, and intrachromosomal mitotic recombination, 154
HLA disease,
mechanisms of predisposition, 37-39
theoretical aspects of disease associations, 39-43
HLA genes,
antigens, 34-45
disease associations, 31-47
genetic mapping of, 33
overview of HLA region, 32-35
See also HLA disease
Holliday junction, 174, 179
Holliday structures, 94-96, 174, 179
Homologous chromosomes, unequal recombination, 153
Homologous recombination, and repeated genes, 148-149
Housekeeping genes, x-linked, 214-216
HPRT genes,
cloning, 214
DNA methylation and X-chromosome expression, 200-202, 210-224
phenotypes of in heterozygous somatic tissue, 203-205
and x reactivation, 221
X-chromosome expression, in extraembryonic lineages and, 207-208
in oogenesis and, 201-202
in preimplantation embryos, 202-203
HSC4 protein, 641
HSC70, 641
multi gene family, 641-645
HSC83, heat shocks and, 635
HSP110, heat shocks and, 634
HSP68 gene, 641
HSP70, 641-652
actions of, 641
characteristic of and of related proteins, 648-656
Clathrin uncoupling ATPase and, 651
Drosophila and, 641-642
Escherichia coli and, 645-648
function of, 652
and GRP 78 protein in mammalian cell line, 651
mammal cells and, 645-648
p72 interactions with cellular tumor antigens, 650-651
Saccharomyces cerevisiae and, 642-645
HSP72 protein, 648-650
HSP83, heat shocks and, 635
HSP90,
biochemical analysis of, 636-639
genetic analysis of, 639-640
heat shocks and, 634-636
"molecular chaperone" with tyrosine kinases, 640
HSPs, *See* Heat-shock proteins
HSV-tk promoter, 498
HTLV 1, and tumorigenesis in transgenic mice, 492
hvp gene, 640
HU, and genetic recombination, 89-90
Human leukocyte antigen, *See* HLA genes
Hunter syndrome, 622
Huntington's disease, 139, 308
genetic markers and, 272-275
Hybrid DNA, *See* hDNA
Hybrid oncogenes,
and additional cell-type specific tumors, 496
and pancreatic oncogenesis in transgenic mice, 495-496
and SV40, 493
targeted expression, 493-497
transformation of lymphoid cells, 493
transformation of mammary glands, 494-493
in transgenic mice, 482-491
unexpected targeting, 496-497
See also Cancer; Oncogenes; Tumorigenesis; Transgenic mice
Hybridization,
between *Lycopersicon* species and *Juglandifolia*, 293-294
plant transformation techniques, 430-441
See also Plant genetics
Hydroxy-acetoxymethyl (OH-AS), 3-5
Hydroxylation reaction, components of, 303-305
5-Hydroxytryptophan, 303
Hyperammonemias, 62
Hyperlipidemia, 274
Hyperphenylalaninemia, 302-314
diagnosis, 312
and enzyme phenotypes, 309
exposure effects during brain development, 310
gene dosage effects, 309-310
and hydroxylation reaction, 303-305

malignant, 305
and enzyme phenotypes, 309
maternal, 313
nomenclature of, 302
and PAH gene haplotypes, 306-307
population genetics, 313-314
treatment approaches, 311-312
Hyperplasias,
cytogenetic progression from hyperplasia to neoplasia, 509-510
receptor induced, 503-504
regenerative induced by cell injury, 504
without frequent progression to tumors, 503-505

I

ICM (inner cell mass), 131-132
IDDM, 31, 40-47
demographics, 44-45
distinguished from NIDDM, 43
genomic imprinting and, 140
hereditary factors, 44-46
and HLA genes, 35-37
IgH (immunoglobulin heavy chain gene), 493
IgH-c-myc and secondary events as progression to neoplasia, 505-508
IHF, binding sites and mechanisms of genetic recombination and, 83-86, 88-91
Immunoglobulin heavy chain gene (IgH), 493, 505-508
Immunology, oncoproteins' influences, 510-512
Imprinting,
germline-specific imprinting of mammalian genomes, 132-135
mechanisms of, 136-142
IncF plasmids,
loop mutations, 577-578
phylogenetic differences, 577-579
IncFII plasmids, 568-571
Influenza, and GRP 78 protein in mammalian cell line, 651
Inner cell mass, 131-132
Insulin dependent diabetes mellitus (IDDM). *See* IDDM
Insulin gene, and pancreatic oncogenesis in transgenic mice, 495-496, 505-508
Insulin promoters, 495-496

Insulin-dependent diabetes mellitus (IDDM), genomic imprinting and, 140
Int, binding sites and mechanisms of genetic recombination and, 87-91, 94
Integration Host Factor (IHF), 80
Interferon-alpha/beta receptor, 54
Intrachromosomal gene conversion, 150-151
Intrachromosomal mitotic recombination, 154-156
MAT locus, 155
Intrachromosomal reciprocal exchange, 151-153
Invariant methods, in studying phylogenies, 547-548
Invertases, synapsis and, 91-94
IPTG-induced cells, mutations and, 663
IQ scores, and hyperphenylalaninemia, 311
IS10, 568-584
and inhibition of gene expression and, 582-584
multicopy inhibition, 571
pairing mechanisms, 589-591, 592-594
stability of, 574-577
synthesis of, 574-577
Islets of Langerhans, and glucagonomas, 495
tumorigenesis in, 505-508

J

Jackknife method,
delete-half method, 552
Lanyon's, 550
in studying phylogenies, 549-553
Japanese, population genetics of variant alleles, 313-314
JC induced neuroblastoma, 491
Jews, population genetics of variant alleles, 306, 313-314
Juglandifolia, hybridization with *Lycopersicon* species, 293-294

K

KAR2 gene, 642, 645
Karyotypes. *See* Gene mapping
Kidney hyperplasia, 503
Kissing reaction, 585-589

L

L-DOPA, and plasma phenylalanine values, 310
Lac-I gene, 159
Lagomorphs. *See* Mammals
Lambda bacteriophages, 80, 176-192, 571-573
See also Bacteriophages;
Phage lambda
See also Phage lambda
Lambda CII, IHF and, 88
Lambda red system, recombination, 175-177
Langer-Giedion syndrome, 621-622
Lanyon's jackknife, in studying phylogenies, 550
Leishmania major, heat-shock proteins and, 633
Leishmaniasis, 633
LEU2 gene, and intrachromosomal gene conversion, 151
LFA-1 (lymphocyte functional antigen-1), 69
Ligands,
ligand synthesis, 65
receptor-mediated phenomena gene dosage effects, 64-66
Likelihood methods,
in phylogenies estimations, 528-529, 534-537
as statistical tests of phylogenies, 543-546
Likelihood ratio test, 543-546
Linkage maps, of tomato, 284-290
LINKAGE program, 264-265, 274
Liposome-encapsulation, of DNA, 434-435
Liver, PAH activity and, 303
Long terminal repeat, and mouse mammary tumor virus, 494
Loop mutations, 577-578
single base mutations, 577-578
Lox, mechanisms of genetic recombination and, 83-86, 94
LRT (Likelihood ratio test), 543-546
LTR, and mouse mammary tumor virus, 494
Lycopersicon esculentum Solanaceae. *See* Tomato
Lycopersicon species,
asexual gene transfer, 294-296

- "*esculentum*" complex, 290
 See also Tomato genetics of, 281-287
 hybridization with *Juglandifolia*, 293-294
 "*peruvianum*" complex, 290
 See also Tomato variability, 290-293
 See also Tomato
- Lymphocyte functional antigen-1 (LFA-1), 69
- Lymphoid cells, development, 505
 transformation of, 493
- Lymphomas, 505
 in transgenic mice, 493-495
- M
- M. leprae*, small HSPs and, 653-658
- M. tuberculosis*, heat-shock proteins and, 633
- M-VATs, antigen expression and, 119-120
- McLeod phenotype (XK), and muscular dystrophy, 605-606
- Maize, biological features, 356-357
 clonal analysis, 362-363
 cytogenetic studies, 373-376
 efficiency in screening, 374-376
 locating genes to chromosome arm, 373-374
 direct gene transfer techniques, 431
 genetic features, 357-358
 genetics of, 356-379
 Maize streak virus, 431
 meristem development, 358-362
 mutations affecting dormancy and germination, 370-371
 mutations affecting embryo morphogenesis, 363-370
 mutations affecting plant morphogenesis, 371-373
 transposon tagging, 376-379
 Maize streak virus, 431
 Major late promoter, definition of, 239
- Malaria, 633
- Malignant hyperphenylalaninemia, 305
 and enzyme phenotypes, 309
- Mammals, androgenones, 130
 aneuploidy in, 53-69
 aneuploidy-induced lethality, 60
- ATPase activity, 644-654
 carnivore genome organization compared with humans, 336-341
 development of parthenogenones in, 129-132
 dosage compensation effects, 55-56
 genetic development of, 127-142
 genome organization, 323-347
 germline-specific imprinting, 132-135
 GRP 78 protein in mammalian cell line, 651
 gynogenones of, 130
 heat-shock proteins and, 632-633
 heat-shock proteins in mammalian cells, 648-652
 HSP70 and mammal cells, 648-652
 imprinting mechanisms, 136-142
 maternal genomes, 130-142
 methods of genetic studies, 128-129
 mice genome organization compared with humans, 331-335
 p72 and HSP70 interactions with cellular tumor antigens in, 650-651
 parthenogenetic activation, 128-129
 paternal genomes, 130-142
 phenotypic abnormalities, 53
 regulatory system effects, 66-68
 specificity in pathogenesis of aneuploidy phenotypes, 60-62
 X-chromosome expression, regulation mechanisms, 199-224
 See also X-chromosome
- Mammary glands, transformation of, 493-494
- Mammary tumorigenesis, See MMTV genes
- Manduca sexta*, and tomato plant genetics, 296
- Marsilea vestita*, 141
- Marsupials, gene maps, 344-345
 X-chromosome inactivation in, 209
- MAT locus, 155
- Maternal genomes, 130-142
 evolutionary implications, 140-142
- Maternal hyperphenylalaninemia, 313
- Maternal PKU, 313
- Mbol*, DNA cloning and muscular dystrophy, 606-612
 pERT reassociation and, 607-609
mdx gene (mouse), 620-621
- Meiotic ectopic recombination, 149-153
 heterochromosomal recombination, 152-153
 and intrachromosomal gene conversion, 150-151
 and intrachromosomal reciprocal exchange, 151-152
 unequal recombination between homologous chromosomes, 153
- Mendelian hyperphenylalaninemia, 302-314
- Mental retardation, and muscular dystrophy, 605-606
- Meristems, development in maize, 358-362
- Meselson-Radding model, 171-173
- Metabolism, receptor-mediated phenomena gene dosage effects, 64-66
- Metacyclic VATs, 119-120
- Metallothionein genes, 497
- Methotrexate, resistance to, 53
- Methylation (DNA), and X-chromosome expression, 200-202, 210-224
- MHC gene, 497
- Mice, DDK and non-DDK incompatibility, 134-135
 gene mapping methodology, 326-328
 genome organization compared with humans, 331-335
 LTK-fibroblasts in, 312
 mouse mammary tumor virus (MMTV), 493-494, 505-508
 mouse NIH 3T3, 312
 Robertsonian translocations during gametogenesis, 132-134
 tumorigenesis in transgenic, 479-514
 See also Transgenic mice
- micF*, and inhibition of gene expression and, 582-584
micF gene, 573-574

- Microorganisms,
and recombination of repeated
genes, 148-163
See also Genetic recombina-
tion; specific organisms
by name
- Miller-Dieker syndrome, 621-
622
- "Mini-exon" genes, 111-112
- Mitochondrial membranes, and
HSP70 function, 646-648
- Mitotic ectopic recombination,
heterochromosomal, 156-157
intrachromosomal mitotic
recombination, 154-156
in yeast, 153-157
- Mitotic recombination, in yeast,
170
- MMTV (mouse mammary tumor
virus), 493-494, 505-508
-c-myc and secondary events
as progression to neoplasia,
505-508
-c-myc and tumor progression
factors, 507-508
and hyperplasias without fre-
quent progression to
tumors, 503-505
MMTV-H-ras genes, 507
- Molecular biology,
inferential methods, 524-529
statistical justifications,
529-544
phylogenies, 521-560
See also Phylogenies
"Molecular chaperone", 640
- Molecular genetics, *See also*
Genetics
- Monogenic disorders, versus an-
euploidy, 52-54
- Monosomies, 58-59
- Morning glory, DNA transfer
and, 20
- Morphogenesis, 353-379
definition of, 354
gene control of, 354-356
biophysical approach,
355
hormonal approach, 354-
355
of maize, 356-379
mutant analysis, 355-356
- mRNA,
BPV-1 and, 237-241
and cellular transformation by
BPV-1, 244-245
cis- and trans-acting elements
in viral transcription,
240-244
- MS (multiple sclerosis), and
HLA genes, 35-37
- Mt-c-fos transgenic mice, 499
- Mueller and Ayala's method, in
studying phylogenies, 549-
550
- Multiple inhibition, 571
- Multiple endocrine neoplasia,
genetic markers and, 272-
275
- Multiple sclerosis (MS), and
HLA genes, 35-37
- Multistep tumorigenesis, 479-
514
- Murine polyoma virus (Py), and
tumorigenesis in transgenic
mice, 492
- Murine retroviruses, 499
- Murine Thy1.1 gene, 503-504
- Murine Thy1.2 gene, 504
- Muscle cells, dystrophin
localization in, 618-619
- Muscular dystrophy, 52, 602-
623
AHC (Adrenal hypoplasia),
605-606
carrier identification, 614-616
CGD (Chronic granulomatous
disease) and, 605-606
creatine kinase (CK) and,
602-603
mDMD gene animal studies,
620-621
DNA cloning and, 606-612
dystrophin and DMD gene,
616-619
dystrophin localization in
muscle cells, 618-619
Emery-Dreifuss muscular
dystrophy, 620-621
glyceraldehyde-3-phosphate
dehydrogenase gene and,
606
glycerol kinase (GK) de-
ficiency and, 605-606
Haldane rule calculations, 603
McLeod phenotype (XK) and,
605-606
Mbol and, 606-612
mdx gene (mouse) and, 620-
621
mental retardation and, 605-
606
molecular genetics of, 603-
612
mutations in DMD gene, 612-
616
pathogenesis of, 619-621
phenol enhanced reassociation
technique (PERT), 606-
612
prenatal diagnosis, 614-616
retinitis pigmentosa (RP) and,
605-606
RFLP markers, 604-605
- X/autosome translocations,
622
See also Becker muscular
dystrophy; Duchenne
muscular dystrophy
- Mutations,
and antisense RNA, 577-579
and conjugative DNA trans-
fer, 19
in DMD gene, 612-616
Hsp synthesis and, 663-664
maize morphogenesis and,
363-373
morphogenesis and, 355-356
population genetics of variant
alleles, 306-308, 313-314
Mycobacterium leprae, heat-
shock proteins and, 633
- N
- N-CAM (Neural cell adhesion
molecule), 68-69
- N-myc gene, 493
- N-ras oncoprotein, 493
- Narcolepsy, and HLA genes,
35-37
- Negative allelic complementa-
tion, definition of, 310
- Neisseria gonorrhoea*, ectopic
recombination, 162
- Neoplasia,
cytogenetic progression from
hyperplasia to neoplasia,
509-510
and induction of preneoplastic
states, 500-501
- Neoplasms, secondary events as
progression, 505-508
- Neural cell adhesion molecule
(N-CAM), 68-69
- Neurofibromas, and HTLV 1,
492
- Neurospora, ectopic recombina-
tion, 162
- NIDDM, distinguished from
IDDM, 43
- NIDDM (Non-insulin dependent
diabetes mellitus), 32
- NIH 3T3 cells (human), 305
- NIH 3T3 fibroblasts (mouse),
312
- Non-insulin dependent diabetes
mellitus (NIDDM), 32, 43
- Nonhousekeeping genes, x-
linked, 216-218
- Nopaline Ti plasmid, 6-13, 24
and T-strand intermediates,
10-13
- NOR (nucleus organizer region),
55
- NTP1 plasmids, 568-571

- Nuclear transfer, in mammalian eggs, 129
- Nucleus organizer region (NOR), 55
- O
- Ochratoxin A, 314
- Octopine Ti plasmid, 5-9 and T-strand intermediates, 10-13
- OH-AS, *See* Hydroxy-acetosyringone (OH-AS)
- Oligonucleotides, GC to CG transversions, 590
- OmpC* protein, 573-574
- OmpF* protein, 568, 573-574
- OmpR* protein, 573-574
- Oncogenes, 480-514
- activation timing, 512
- cytogenetic progression from hyperplasia to neoplasia, 509-510
- deregulated expression of, 497-498
- embryonal carcinoma cell expression of X-chromosome, 203-205
- gene amplification, 53-54
- HLA genes, 31-47
- horizontal viral infections versus gene line transmission, 511
- hyperplasias without frequent progression to tumors, 503-505
- induction of preneoplastic states, 500-505
- lymphoid cells transformation, 493
- mammary glands transformation, 494-493
- natural regulatory elements, 484-492
- proliferative capability, 501-502
- recessive cytogenic changes, 509-510
- regenerative hyperplasia induced by cell injury, 504
- secondary events as progression to neoplasia, 505-508
- targeted expression of hybrid oncogenes, 493-497
- in transgenic mice, 482-491
- tumor progression factors, 507-508
- See also* Hybrid oncogenes; Oncoprotein action; Transgenic mice; Tumorigenesis
- Oncoproteins,
- actions of, 499-5012
- function of, 504-505
- immunological influences, 510-512
- and induction of preneoplastic states, 500-501
- and proliferative capability of pancreatic cells, 501-502
- Oocytes, X-chromosome expression in oogenesis and, 201-202
- Oogenesis, X-chromosome expression in, 201-202
- OOP, phage lambda and, 572-573
- oopRNA*, 584
- Organic acidemias, 62
- Ornithine decarboxylase induction, *c-Ha-ras* oncogene effects, 66
- Ornithine transcarbamylase (OTC) gene, expression of, 217-218
- Osmoregulation, in *Escherichia coli*, 573
- OTC gene, expression of, 217-218
- OTF9-63 cells, 204
- Ova,
- mammalian, 128-129
- mammalian imprinting mechanisms and, 136-142
- X-chromosome expression in preimplantation embryos, 202-203
- Overdrive sequence, T-DNA, 8-9
- Overlap homology, in genetic recombination, 83-84
- P
- P Ant, and temporal regulation of phage development, 571-573
- P Sar, and temporal regulation of phage development, 571-573
- p15A plasmids, 568-571
- P22 *sar*,
- and inhibition of gene expression and, 582-584
- pairing reactions, 591-594
- and stem-loop structures of antisense RNA, 574
- P22, and temporal regulation of phage development, 571-573
- PAH gene, 302-314, 312, 314
- chromosomal locus, 305
- cloning of, 305-306
- description of, 303-304
- and enzyme phenotypes, 308-310
- gene dosage effects on hyperphenylalaninemia, 310
- haplotypes, 306
- and liver activity, 303
- mutations of, 306-307
- phosphorylation-dephosphorylation of subunit, 304
- PKU-causing alleles, 306-307
- rat PAH (25), 305
- structure of, 306
- and TYH brain activity, 303
- Pairing reactions,
- antisense RNA and, 585-594
- GC to CG transversions, 590
- p22 *sar*, 591-594
- PAL, 314
- phenylalanine conversion, 312
- Pancreas,
- Beta cells' proliferative capabilities, 501-502
- hyperplasias without frequent progression to tumors, 503-505
- oncogenes in transgenic mice, 495-496, 505-510
- Papillomavirus,
- bovine type 1, *See* BPV-1
- Shope papillomavirus, 235
- PAQ, phage lambda and, 572-573
- Parthenogenesis, maternal and paternal genomes of mammals, 130-142
- Parthenogenetic activation, development of parthenogenones in mammals, 129-132
- in mammals, 128-129
- Paternal genomes, 130-142
- PEG fusion promoter, 204
- Penny and Hendy's resampling method, in studying phylogenies, 552-553
- Peripheral neurofibromatosis, genetic markers and, 272-275
- Perissodactyls, *See* Mammals
- PERT,
- and cloning of DNA segments from DMD locus, 606-612
- Mbol* and, 607-609
- Petunia, DNA transfer and, 20
- PGK gene,
- cloning of, 215

- DNA methylation and X-chromosome expression, 212, 215
- PGK-1 allozyme, embryonal carcinoma (EC) cell expression, 203
- PGK-1 gene, X-chromosome expression in extraembryonic lineages and, 207-208
- Phage lambda, 177-192
and *cos* function, 176-177
DNA replication, 645-648
double-chain breaks, 177-189
and *groE* genes of *E. coli*, 652-653
homologous recombination, 173-174
OOP and, 572-573
PAQ and, 572-573
recBCD, 175-176
repair of double-chain breaks, 178-182
and temporal regulation of phage development, 571-573
- Phenol enhanced reassociation technique (pERT), 606-612
- Mbol* and, 607-609
- Phenotypes,
aneuploidy and, 52-53
of enzymes, 308-310
genetic analysis of HSP90, 639-640
of gynogenetic and androgenetic embryos, 131-132
of HPRT in heterozygous somatic tissue, 203-205
McLeod phenotype (XK), 605-606
metabolic and functional, 310-311
monosomies and trisomies, 58-59
pathogenesis of aneuploidy phenotypes, 60-62
phenotypic maps, 58
principles derived from human clinical material, 56-63
of X-chromosome, 606-612
- Phenylalanine, 302-314
conversion to tyrosine, 305
definition of, 302
and hydroxylation reaction, 303-305
and maternal hyperphenylalaninemia, 313
PAL conversion, 312
plasma phenylalanine values, 310
- in treatment of hyperphenylalaninemia and PKU, 311-312
- Phenylalanine ammonia lyase, *See* PAL
- Phenylalanine hydroxylase, *See* PAH
- Phenylketonuria, *See* PKU
- Phenylpropanoid metabolism, 3
- Phosphate-eliminating enzyme, 304-305
- Phosphorylation, of HSP90, 636-639
- Phylogenies, 521-560
estimations of, 522-524
inferential methods, 524-529
compatibility, 526, 532-533
distance matrix methods, 526-528, 530-532
likelihood methods, 528-529, 534-537
parsimony, 524-526, 532-533
simulation studies, 553-556
statistical tests, 537-560
bootstrap method, 548, 550-552
Cavender's confidence interval, 537-539
delete-half method, 552
distance methods, 541-543
F tests, 541
jackknife, 549-553
Lanyon's jackknife, 550
likelihood methods, 543-546
Mueller and Ayala's method, 549-550
Penny and Hendy's resampling method, 552-553
relative rate test, 541-542
resampling methods, 544-553
Sneath's distance triads, 540-541
Templeton's pairwise test, 540
variances of branch lengths, 542
statistical used in studies of, 529-560
- Pin system, and genetic recombination, 81-82
- PKU, 302, 302-314
alleles, 306-307
prevalence and distribution, 307-308
diagnosis, 312
and enzyme phenotypes, 308-310
- expression of and PAH activity, 303
maternal, 313
PAH alleles, 306-307
and plasma phenylalanine values, 310-311
population genetics, 313-314
treatment approaches, 311-312
See also Hyperphenylalaninemia
- Plant cell recognition, 2
- Plant cell transformation, *Agrobacterium*-mediated, 1-24
See also T-DNA
- Plant engineering, *See* Plant genetics
- Plant genetics, 421-460
Agrobacterium tumefaciens and natural plant engineering, 422-428
engineering applications, 457-460
gene vectors derived from the Ti plasmid, 423-428
of maize, 356-379
meristems, 358-362
plant promoters, 443-457
plant transformation techniques, 429-435
Agrobacterium tumefaciens and *Agrobacterium rhizogenes*, 429-430
direct gene transfer, 431-434
liposome-encapsulation of DNA, 434-435
microinjection, 434-435
protoplast fusion, 434-435
viral vectors, 430-431
of potato, 293-294
of tomato, 281-287
transgenic plants, 435-457
expression of transferred genes in, 441-457
structure and inheritance, 435-437
See also Maize; Tomato; specific plants by name
- Plasma phenylalanine values, 310
- Plasmid antisense systems, 568-571
See also Antisense RNA; Plasmids
- Plasmid replication, 245-249
two-stage model, 249
- Plasmid segregation, 81
- Plasmids, and antisense RNA, 568-571
- Plasminogen, deficiencies of, 64
- Plasmocytomas, in transgenic mice, 493-494

- Plasmodium falciparum*, heat-shock proteins and, 633
 pMB1 plasmids, 568-571
 Polyadenylation signals, 239-241
 Polyclonal pre-B cells, 501
 Polypeptides, *vir* region of the octopine Ti plasmid and, 5-8
 Potato, hybridization with *Lycopersicon* species, 293-294
 Preimplantation embryos, X-chromosome expression, 202-203
 Prenatal diagnosis, of muscular dystrophy, 614-616
 Preneoplastic states, induction of, 500-505
 Preproglucagon gene, and pancreatic oncogenesis in transgenic mice, 495-496
 Primates, gene mapping methodology, 328-331
 See Mammals
 Primer formation, inhibition of, 588-589
 Progesterone, 637
 Prokaryotes, factors influencing recombination, 160-161
 heat-shock proteins, 661
 recombination between repeated genes, 157-161
 Promoters, expression controlled by plant promoters, 454-457
 major late promoter, 239
 and pancreatic oncogenesis in transgenic mice, 495-496
 PEG fusion promoter, 204
 promoter genes, 497-499
 viral promoters in transgenic plants, 443, 454
 viral transcriptional promoters, 239-241
 Proteins, accessory proteins in genetic recombination, 88-91
 DNA binding, 14-15
 E2 factors in viral transcription, 240-244
 eukaryotes, 659-661
 heat-shock, 632-667
 See also Heat-shock proteins
 lambda DNA replication, 645-648
 OmpC protein, 573-574
 OmpF protein, 573-574
 OmpR protein, 573-574
 oncoprotein action, 499-501
 prokaryotes, 661
 Rom/Rop, 589
 small HSPs and, 653-658
 synthesis of and two-dimensional gel electrophoresis, 62-63
 ubiquitin, 658-659
 See also Heat-shock proteins
 See also HSC70; HSP68
 gene; HSP70
 Protoplast fusion, plant hybrids and, 434-435
 Protuberant tumor, of skin, 509-510
 PstI, 110
 pT181 plasmids, 569-571
 6-PTS, 302-312
 diagnosis of deficiencies, 312
 and enzyme phenotypes, 309
 gene dosage effects on hyperphenylalaninemia, 310
 and hydroxylation reaction, 303-305
 and neurotransmitter depletion, 311
 population genetics of variant alleles, 313-314
 purification of, 305
 PvuII, 110
 Py large T, 500
 Py middle T, 500
 6-Pyruvoyl tetrahydropterin synthase, *See* 6-PTS
 Q
 Q fever, 633
 Q-bands, aneuploidy and, 59-60
 Quinonoid form of dihydrobiopterin, *See* qBH 2
 R
 R1162, and inhibition of gene expression and, 582-584
 plasmids, 569-571
 R-bands, aneuploidy and, 59-60
 RA (rheumatoid arthritis), and HLA genes, 31, 35-37
 RAD52 gene products, 155
 Rat PAH (25), 305
 Rb gene, 480
 Rec-A dependent process, and ectopic recombination, 162
 RecBCD, 176-178
 and Chi nicking, 177
 double-chain break repair, phage lambda, 178-182
 yeast, 182-187
 of *E. coli*, 175-176
 and lambda red system, 175-177
 paradox, 191-192
 recombination and, 169
 RecE, and lambda red system, 175-177
 Receptors, in aneuploidy situation, 54
 receptor-induced hyperplasias, 503-504
 receptor-mediated phenomena
 gene dosage effects, 64-66
 RecF, and lambda red system, 175-177
 Recombinant oncogenes, *See* Oncogenes
 Recombinases, mechanisms of genetic recombination and, 86-90
 Recombination, frequency estimates, 269-270
 homologous and repeated genes, 148-149
 of repeated genes, 148-163
 Smith's nick-at-Chi model, 178-179, 187-191
 See DNA recombination; Genetic recombination
 Red system, recombination, 175-177
 Red-sensitive visceral pigment (*Rsvp*), 224
 Regenerative hyperplasia, induced by cell injury, 504
 Regulatory systems, and aneuploidy, 65-68
 Relative rate test, in studying phylogenies, 541-542
 Repeated genes, mitotic ectopic recombination, 153-157
Res sites, and genetic recombination, 88-90
 Resampling methods, in studying phylogenies, 544-553
 Resnick's recombination model, 170-173
 Resolvase, synapsis and, 91-94
 Restriction enzymes, antigen gene expression site and, 110
 Restriction fragment length polymorphisms (RFLPs), 32-34, 39, 46, 306, 313-314, 480
 See also RFLPs
 Reticulum cell lymphoma, 493
 Retinitis pigmentosa, genetic markers, 272-275
 Retinitis pigmentosa (RP), and muscular dystrophy, 605-606
 Retinoblastoma, 67, 480, 621-622
 Reverse genetics, disease applications, 621-623

- RFLPs, 39, 46, 480
 haplotypes and PAH gene, 306
 in human populations, 324
 and molecular genetics of of muscular dystrophy, 604-605
 population genetics of variant alleles, 313-314
 tomato, 285
- RFLPs (Restriction fragment length polymorphisms), 32, 33-34
- Rheumatoid arthritis (RA), 31
 and HLA genes, 35-37
- Rhizobium* specific genes, 3-4
- Ribosomal DNA, See rDNA
- Ribosome binding sites, and inhibition of gene expression and, 582-584
- RNA, 510
 antisense, 568-594
 ColEI and, 568-570
 inhibition effects, 579-584
 plasmid antisense systems, 568-571
 See Antisense RNA
 GC to CG transversions, 590
 HSP110 and heat shocks, 634-636
 HSP90 and heat shocks, 634-636
 and inhibition of gene expression and, 582-584
 IS10 and, 589-591
 kissing reaction, 585-589
 markers and disease, 275-277
 mutations and, 577-579
 OOP and antisense control, 572-573
 p22 *sar* pairing reactions, 591-592
 PAQ and antisense control, 572-573
 and plant genetics, 422-460
 RNA-OUT, 574-577
 Rom/Rop protein and, 589
 snRNA, See snRNAs
 spliceosomal snRNAs, 387-416
 See also snRNAs
*tic*RNA and transcription of bacterial genes, 574
 transcription and antisense, 579-584
 transcriptional effects and RNase III cleavage, 582
 See also Antisense RNA
- mRNA,
 antigen gene transcription and, 111, 119
 dosage compensation effects, 55-56
 and inhibition of gene expression and, 582-584
 and PAH gene, 308
 in rodent kidneys, 303
- rRNA,
 and intrachromosomal mitotic recombination, 154
 and recombination between repeated genes, 161-162
 of *Xenopus*, 55
- sar*RNA, 571-573, 591-592
- snRNA,
 background, 388-390
 dosage compensation effects, 55-56
 function of, 391-395
 splicing, 387-416
 structure of, 390-391
 U1 analogues, 404-405
 U2 analogues, 406-414
 U4 and U6 analogues, 395-400
 U5 analogues, 400-404
- tRNA, and heterochromosomal recombination, 152-153
- tic*RNA, and transcription of bacterial genes, 574
- RNA I, 577-584
 binding, 581
 kissing reaction, 585-589
 transcriptional effects and RNase III cleavage, 582
- RNA II,
 antisense inhibition effects, 579-584
 binding, 581
 bypass of antisense control and, 584-585
 kissing reaction, 585-589
- RNA polymerase,
 antigen gene transcription unit and, 111
 antisense inhibition effects, 579-584
- RNA polymerase holoenzyme, 4
- RNA-IN, IS10 and, 590-591, 592-594
- RNA-OUT, 583-584
 IS10 and, 589-591, 592-594
- RNase, heat shocks and, 634-636
- RNase III, 580-584
- RNaseH, antisense inhibition effects, 579-584
- Robertsonian rearrangements, in carnivores, 340-341
- Robertsonian translocations, 132-134
- Rodents, See Mammals; Mice
- Rom/Rop proteins, 589
- Rous Sarcoma Virus, 636
- Rous sarcoma virus long terminal repeat (RSV-LTR), 136
- RSF1030 plasmids, 568-571
- RSV-LTR (Rous sarcoma virus long terminal repeat), 136
- S
- S. mansoni*, small HSPs and, 653-658
- Saccharomyces cerevisiae*, 148
 biochemistry of HSP90 and, 638
 CSSR encoding, 82
 hDNA and double-chain breaks, 171
 genetic analysis of HSP90, 639-640
 and heat-shock proteins, 634-635, 660
 and heterochromosomal mitotic recombination, 156-157
 and heterochromosomal recombination, 152-153
 HSP70 and, 642-645
 and intrachromosomal gene conversion, 150-151
 and intrachromosomal mitotic recombination, 154-156
 MAT locus, 155
 small HSPs and, 653-658
 U1, U2, U3, U4, U5 and U6 analogues, 400-413
- Salmonella* phage P, and temporal regulation of phage development, 571-573
- Salmonella typhimurium*, 148
 and genetic recombination, 81-82
 prokaryotes and recombination, 158-161
- Sar*,
 p22 *sar* pairing reactions, 591-592
 See also P22 *sar*
sar RNA, 571-573
- Scandinavian populations, population genetics of variant alleles, 306
- Schistosoma mansoni*, heat-shock proteins and, 633
- Schizosaccharomyces pombe*, 148
 and heterochromosomal mitotic recombination, 156-157
 and heterochromosomal recombination, 152-153
 MAT locus, 155
- Septaplerin-synthesizing enzyme, 304-305

- Shope papillomavirus, 235
 Sickle cell anemia, 313
 Simulation studies, in estimating phylogenies, 553-556
 Single base mutations, and antisense RNA, 577-578
 Site-specific recombination, 78-97
 homologous differentiated from, 77-78
 integration and excision systems, 80
 See also Genetic recombination
 Skin, tumorigenesis in transgenic mice, 509-510
 Small HSPs, structure and actions of, 653-658
 Smith's nick-at-Chi model, 178-179, 187-191
 Sneath's distance triads, 540-541
 SOS response, 661
 Spastic paraplegia, genetic markers, 272-275
 Sperm development, and high temperatures, 662
 SphI, 110
 Spliceosomal snRNAs, 387-416
 Spontaneous parthenogenesis, 129
 SSA genes, 642-645
 SSB genes, 642-645
 protein encoding and F plasmid, 18
 SSC genes, 642-645
 Statistics,
 bootstrap method in studying phylogenies, 548, 550-552
 Cavender's confidence interval, 537-539
 delete-half method in studying phylogenies, 552
 distance methods, 541-543
 F tests in studying phylogenies, 541
 and inferential methods in estimating phylogenies, 529-560
 invariant methods, 547-548
 jackknife method, 549-553
 Lanyon's jackknife in studying phylogenies, 550
 likelihood methods, 543-546
 Mueller and Ayala's method, 549-550
 Penny and Hendy's resampling method, 552-553
 relative rate test, 541-542
 resampling methods, 549-553
 Sneath's distance triads, 540-541
 Templeton's pairwise test, 540
 tests of phylogenies, 537-560
 variances of branch lengths in studying phylogenies, 542
 Strand exchange,
 Holliday structures, 94-96
 synapsis and, 91-94, 96
 Sunflower, DNA transfer and, 20
 Sup genes, and heterochromosomal recombination, 152-153
 SV40,
 and hybrid oncogenes, 493
 immunological characteristics, 511-512
 and p72 and HSP70 interactions with cellular tumor antigens, 650-651
 and pancreatic oncogenesis in transgenic mice, 495-496
 T antigen, 493-505, 511-512
 and hyperplasias without frequent progression to tumors, 503-505
 immunological characteristics, 511-512
 and oncoprotein action, 499-501
 and proliferative capability of pancreatic cells, 501-502
 tumorigenesis and, 491-512
 Synapsis, genetic recombination and, 91-94
 T
 T4 bacteriophage, recombination, 170
T. b. gambiense, 108, 121
 See also Trypanosomes
T. b. rhodesiense, 108
 See also Trypanosomes
T. brucei, 117-118, 121
 antigenic switching in, 114-116
T. cruzi, 110-111
 See also Trypanosomes
T. equiperdum, 108
 See also Trypanosomes
 T antigens, 497-498
 elastase-T antigen transgene, 501
 large and small, 493
 and oncoprotein action, 499-501
 and pancreatic oncogenesis in transgenic mice, 495-496
 stability of p53 in SV40 transformed cells, 650-651
 SV40 T antigen, 493-505, 511-512
 in transgenic mice, 511-512
 and tumorigenesis in transgenic mice, 492
T. evansi, 108
 See also Trypanosomes
 T-cell lymphoma, in transgenic mice, 493-494
 T-DNA,
 Agrobacterium chromosome, 2-3
 Agrobacterium tumefaciens and, 1-25
 bacterial conjugation versus T-DNA transfer, 16-19
 border regions, 7-11
 crown gall tumors and, 1-2
 integration into plant genome, 19-22
 model for transfer mechanism, 15-16
 overdrive sequence, 8-9
 structural requirements for transfer, 6-9
 topology of T-DNA region, 23
 transfer intermediates, 9-15
 transfer process border interactions, 6-8
 vir region of the octopine Ti plasmid, 5-8
 See also DNA
 T-strand, as transfer intermediate, 10-17
 Targeted expression, of hybrid oncogenes, 493-497
tatI gene, and tumorigenesis in transgenic mice, 492
 Telomeres,
 ESAG carrying, 112-115
 structure of, 109
 Templeton's pairwise test, 540
 Tetrahydrobiopterin (6R)—*erythro* 5,6,7,8, 56
 tetrahydrobiopterin, See BH 4
Tetrahymena, antigen gene variation, 116
 TH (tyrosine hydroxylase), 502
 Thalassemia, 306, 313
 Thermotolerance, 661-663
 correlation between Hsp synthesis and, 662-663
 and genetics, 639-640
 mutations and Hsp synthesis, 663-664
 and small HSPs, 656-657
 See also Heat-shock proteins
 Ti plasmids, 1-4

- Agrobacterium tumefaciens*
and natural plant
engineering, 422-428
nopaline, 6-9
Octopine, 5-9
plant gene vectors derived
from, 423-428
and T-strand intermediates,
10-13
transfer process and, 9-11
vir region of the octopine Ti
plasmid, 5-8
tic RNA, 583
and transcription of bacterial
genes, 574
Tissue hyperplasia, and induction
of preneoplastic states,
500-501
TKCR syndrome, 622
Tobacco, DNA transfer and,
20
tolC, 573-574
Tomato, 281-287
asexual gene transfer, 294-
296
developmental gene express,
283-284
DNA transfer and, 20
EPSP synthase, 296
genetic variability, 290-296
genetics of, 281-297
genome of, 282-283
heat-shock proteins and, 656-
657
linkage, 284-290
mapping of, 284-290
species of, 290-293
TPH (tryptophan hydroxylase),
302-314
traJP genes, 570-571
Transgenes, 135-136
Transgenic mice,
and BK virus, 491-492
generation of, 481-482
and hyperplasias without fre-
quent progression to
tumors, 503-505
immunological characteristics,
511-512
induction of preneoplastic
states, 500-505
JC induced neuroblastoma in,
491
lymphoid cell transformations,
493, 505-508
mammary gland transforma-
tions, 493-494
MT-*c-fos*, 499
oncogenes in, 482-491
and oncoprotein action, 499-
501
pancreatic oncogenesis, 495-
496, 505-508, 509-510
recessive cytogenic changes,
509-510
skin tumors, 509-510
T antigen, 511-512
targeted expression via hybrid
oncogenes, 493-497
tumor progression factors,
507-508
tumorigenesis in, 479-514
Transgenic plants, 435-457
expression of transferred
genes in, 441-457
bacterial, plant, and animal
genes, 442-443
expression assays, 441-442
expression controlled by T-
DNA, 443,
454
viral promoters, 443, 454
structure, inheritance, and
function, 435-457
See also Plant genetics
Translocation exchange, of
Xp21 band and muscular
dystrophy, 604
Transport systems, enzyme reac-
tions and gene dosage
effects, 64-66
Transposon,
cointegrate resolution, 80-81
tagging in maize, 376-379
TRH, 302-312, 311
and enzyme phenotypes,
309
and hydroxylation reaction,
304
Trisomies, 58-59
Trisomy, for *Drosophila*, 55
TRS-1 retrotransposon, 111-112
Trypanosoma b. brucei, 108-111
See also Trypanosomes
Trypanosoma cruzi, heat-shock
proteins and, 633
Trypanosoma (Duttonella) vivax,
108
See also Trypanosomes
Trypanosoma (Nannomomonas)
congolense, 108-110
See also Trypanosomes
Trypanosomes,
antigen gene expression site,
109-110
antigen gene repertoire, 108-
109
antigen gene single site ex-
pression site mech-
anisms, 112-114
antigen gene transcription
unit, 110-112
antigenic variation in blood,
114-116
life cycle of African trypano-
somes, 107-108
molecular basis for timing in
antigen expression, 116-
118
stage-dependent regulation of
antigen gene expression
sites, 118-120
Tryptophan, 302
Tryptophan hydroxylase, *See*
TPH
Tuberculosis, 633
Tumorigenesis,
and B-cell tumors, 501
and BK virus, 491-492
and BPV-1, 492
of CHEF/18, 66
chromosome characterization,
276-277
and deletion of human
chromosome region
13q14, 67
dominant transforming genes,
480
genetics of, 479-514
heterozygosity and, 480
and HLA disease associations,
35-47
and HTLV 1, 492
hyperplasias without frequent
progression to tumors,
503-505
induction of preneoplastic
states, 500-505
and JC induced neuroblasto-
ma, 491
multistep, 479-514
oncogenes and natural regula-
tory elements, 484-492
oncogenes in transgenic mice,
482-491
and oncoprotein action, 499-
501
pancreatic, 509-510
and pancreatic oncogenesis
in transgenic mice, 495-
496
proliferative capability, 501-
502
recessive cytogenic changes,
509-510
and regenerative induced by
cell injury, 504
secondary events as progres-
sion to neoplasia, 505-
508
of skin, 509-510
and SV40, 491
and T antigens, 492
targeted expression of hybrid
oncogenes, 493-497
tumor progression factors,
507-508
See also HLA disease; Muta-
tions; Oncogenes

- Tumors,**
 B-cell lymphoma, 493
 choroid plexus, 491
 chromosome characterization
 by genetic markers, 276-
 277
 development of, 479-480
 immunological influences,
 510-512
 p72 and HSP70 interactions
 with antigens, 650-651
 skin, 509-510
 transgenic progression factors,
 507-508
 types of, 484-490
 Wilm's tumor, 480
See also Tumorigenesis
 2-D protein patterns, 62-63
 Two-dimensional gel elec-
 trophoresis, of protein syn-
 thesis, 62-63
Ty elements, CYC1 gene and
 intrachromosomal mitotic
 recombination, 154-155
TYH,
 and enzyme phenotypes, 309
 and hydroxylation reaction,
 304
 and PAH brain activity, 303
TYH (tyrosine hydroxylase),
 302-314, 311, 502
Tyrosine, 302
 conversion from phenylala-
 nine, 305
 Tyrosine hydroxylase, *See* TYH
 Tyrosine hydroxylase (TH),
 302-314, 502
 Tyrosine kinases,
 HSP90 and, 636-639
 "molecular chaperone" with
 HSP90, 640
U
 Ubiquitin, 658-659
 Unequal recombination, between
 homologous chromosomes,
 153
 Ursidae, chromosome shuffles
 in, 338-341
V
 v-abl gene, 493
 Variable Number Tandem Re-
 peat (VNTR) systems, 263-
 264
 Vascular endothelial tumors, and
 oncoprotein specificity, 499
Vibrio cholerae, ectopic
 recombination, 162
 Vir gene expression, 3-6
 Vir region,
 definition of, 2
 of octopine Ti plasmid, 5-8
 Viral transcription,
 of BPV-1, 237-244
 cis-acting factors, 240-244
 E2 factors, 240-244
 mRNA species, 237-239
 physical map, 237
 promoters, 237-241
 trans-acting factors, 240-
 244
 cis- and trans-acting elements,
 240-244
 trans-acting factors and plas-
 mid replication, 246-249
 transcriptional promoters,
 239-241
 Virulence region, *See* Vir region
 Virulence-related proteins,
 and *Agrobacterium tumefa-*
 ciens, 6
See also Vir region
Viruses,
 Bovine papillomavirus type 1
 BPV-1, 235-254
See also BPV-1
 Rous Sarcoma Virus, 636
 Shope papillomavirus, 235
 viral DNA replication, 245-
 251
 viral promoters in transgenic
 plants, 443, 454
 viral vectors and plant
 transformation tech-
 niques, 430-431
See also mRNA; Viral
 transcription
 VNTR (Variable Number Tan-
 dem Repeat) systems, 263-
 264
 VRPs, *See* Virulence-related
 proteins
W
 WAGR complex, 621-622
 WAP gene, 494
 Watson strands, 95
 Whey acid protein gene
 (WAP), 494
 Wild-type recombination, 175
 Wilms tumor, 276
 Wilm's tumor, 480
 Wilms tumor, 621-622
X
X. laevis, small HSPs and, 653-
 658
 X-chromosome,
 carrier identification of
 muscular dystrophy and,
 614-616
 cloning of DNA and muscular
 dystrophy, 606-612
 DNA methylation, 200-202,
 210-224
 embryonal carcinoma cell ex-
 pression, 203-205
 establishment mechanisms,
 218-221
 evolutionary implications,
 140-142
 inactivation in extraembryonic
 lineages, 206-208
 in marsupials, 209
 and molecular genetics of of
 muscular dystrophy, 603-
 612
 oogenesis expression, 201-202
 preimplantation embryo ex-
 pression, 202-203
 reactivation, 221-224
 regulation mechanisms, 199-
 224, 218-224
 regulation of, DNA methyla-
 tion, 200-202, 210-224
 single active X expression,
 205-206
 x-linked housekeeping genes,
 214-216
 x-linked nonhousekeeping
 genes, 216-218
 X/autosome translocations,
 622
 X-linked disorders, 52-53
 X-linked traits, muscular dystro-
 phy and, 602-603
 X-ray crystallographic studies,
 of Rom/Rop proteins, 589
 X/autosome translocations,
 BMD and DMD, 622
Xenopus, 660
 autosomal damage to, 55
 rRNA and, 162
 Xis, and genetic recombination,
 89-90
 XK phenotype (McLeod), and
 muscular dystrophy, 605-
 606
 Xp21,
 and contiguous gene syn-
 dromes, 622
 and molecular genetics of of
 muscular dystrophy, 603-
 612
Y
 Yeast,
 double-chain break repair,
 182-187
 mitotic ectopic recombination,
 153-157
 Yemenite Jews, population ge-
 netics of variant alleles,
 306, 313-314
Z
 Zebra fish, cloning of, 140-141

